Technical Analysis for NVAX - Novavax, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Centerline Cross | Bearish | 0.00% | |
| Stochastic Buy Signal | Bullish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.55% | |
| Down 3 Days in a Row | Weakness | 0.55% | |
| Down 4 Days in a Row | Weakness | 0.55% | |
| Oversold Stochastic | Weakness | 0.55% | |
| New Downtrend | Bearish | -0.78% | |
| Narrow Range Bar | Range Contraction | -0.78% |
| Alert | Time |
|---|---|
| Down 1% | about 7 hours ago |
| 60 Minute Opening Range Breakdown | about 7 hours ago |
| 10 DMA Resistance | about 10 hours ago |
| Rose Above Previous Day's High | about 10 hours ago |
| Up 5% | about 10 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 08/06/2024
Novavax, Inc. Description
Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases. The company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles (VLPs) and recombinant protein micelle vaccines. Its vaccine candidates target seasonal influenza, pandemic (H5N1) influenza, and respiratory syncytial virus (RSV). The company, through its joint venture, CPL Biologics Private Limited, engages in developing seasonal and pandemic influenza, and rabies vaccine candidates. The company has a licensing agreement with LG Life Sciences, Ltd. to use the company's VLP technology to develop and sell the influenza vaccines in South Korea and other countries; and a clinical development agreement with PATH Vaccine Solutions to develop RSV vaccine candidate. The company was founded in 1987 and is headquartered in Rockville, Maryland.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Infectious Diseases Clinical Development Vaccines Influenza Coronavirus Vaccination Influenza Vaccine Seasonal Influenza Rabies
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 23.8599 |
| 52 Week Low | 3.5324 |
| Average Volume | 18,913,939 |
| 200-Day Moving Average | 7.01 |
| 50-Day Moving Average | 11.73 |
| 20-Day Moving Average | 15.40 |
| 10-Day Moving Average | 13.52 |
| Average True Range | 1.37 |
| RSI (14) | 43.18 |
| ADX | 24.99 |
| +DI | 25.47 |
| -DI | 24.15 |
| Chandelier Exit (Long, 3 ATRs) | 19.75 |
| Chandelier Exit (Short, 3 ATRs) | 16.46 |
| Upper Bollinger Bands | 20.12 |
| Lower Bollinger Band | 10.68 |
| Percent B (%b) | 0.22 |
| BandWidth | 61.33 |
| MACD Line | -0.05 |
| MACD Signal Line | 0.56 |
| MACD Histogram | -0.6063 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 14.70 | ||||
| Resistance 3 (R3) | 14.82 | 14.29 | 14.37 | ||
| Resistance 2 (R2) | 14.29 | 13.79 | 14.23 | 14.26 | |
| Resistance 1 (R1) | 13.51 | 13.48 | 13.90 | 13.39 | 14.15 |
| Pivot Point | 12.98 | 12.98 | 13.18 | 12.92 | 12.98 |
| Support 1 (S1) | 12.20 | 12.48 | 12.59 | 12.08 | 11.31 |
| Support 2 (S2) | 11.67 | 12.17 | 11.61 | 11.20 | |
| Support 3 (S3) | 10.89 | 11.67 | 11.09 | ||
| Support 4 (S4) | 10.77 |
